pSivida’s lead investigational new product is a three-year sustained-release implant containing fluocinolone acetonide , a corticosteroid, in late stage clinical development for the treatment of posterior uveitis. The product utilizes the proven Durasert Technology platform. The first Phase 3 study achieved its primary endpoint with high statistical significance. The second Phase 3 study results are expected first half of 2017. Filing in the EU is anticipated first half of 2017 and second half of 2017 in the U.S.
- pSivida to Present at Canaccord Genuity Growth Conference onÂ August 10, 2017
- Leading Retinal Specialists to Highlight pSivida’s Durasert for Treatment of Posterior Segment Uveitis at Prestigious Ophthalmology Conferences
- pSivida Out-licenses EMEA Rights for Durasertâ„¢ Three-year Treatment for Posterior Segment Uveitis While Retaining U.S. Commercial Rights; Amended Global Collaboration Agreement with Alimera for ILUVIENÂ® Improves pSivida’s Revenue Generation